Literature DB >> 28052152

Types of Myocardial Infarction Among Human Immunodeficiency Virus-Infected Individuals in the United States.

Heidi M Crane1, Pathmaja Paramsothy1, Daniel R Drozd1, Robin M Nance1, J A Chris Delaney2, Susan R Heckbert3, Matthew J Budoff4, Greer A Burkholder5, James H Willig5, Michael J Mugavero5, William C Mathews6, Paul K Crane1, Richard D Moore7, Joseph J Eron8, Sonia Napravnik8, Peter W Hunt9, Elvin Geng9, Priscilla Hsue9, Carla Rodriguez1, Inga Peter10, Greg S Barnes11, Justin McReynolds11, William B Lober11, Kristina Crothers1, Matthew J Feinstein12, Carl Grunfeld9, Michael S Saag5, Mari M Kitahata1.   

Abstract

Importance: The Second Universal Definition of Myocardial Infarction (MI) divides MIs into different types. Type 1 MIs result spontaneously from instability of atherosclerotic plaque, whereas type 2 MIs occur in the setting of a mismatch between oxygen demand and supply, as with severe hypotension. Type 2 MIs are uncommon in the general population, but their frequency in human immunodeficiency virus (HIV)-infected individuals is unknown.
Objectives: To characterize MIs, including type; identify causes of type 2 MIs; and compare demographic and clinical characteristics among HIV-infected individuals with type 1 vs type 2 MIs. Design, Setting, and Participants: This longitudinal study identified potential MIs among patients with HIV receiving clinical care at 6 US sites from January 1, 1996, to March 1, 2014, using diagnoses and cardiac biomarkers recorded in the centralized data repository. Sites assembled deidentified packets, including physician notes and electrocardiograms, procedures, and clinical laboratory tests. Two physician experts adjudicated each event, categorizing each definite or probable MI as type 1 or type 2 and identifying the causes of type 2 MI. Main Outcomes and Measures: The number and proportion of type 1 vs type 2 MIs, demographic and clinical characteristics among those with type 1 vs type 2 MIs, and the causes of type 2 MIs.
Results: Among 571 patients (median age, 49 years [interquartile range, 43-55 years]; 430 men and 141 women) with definite or probable MIs, 288 MIs (50.4%) were type 2 and 283 (49.6%) were type 1. In analyses of type 1 MIs, 79 patients who underwent cardiac interventions, such as coronary artery bypass graft surgery, were also included, totaling 362 patients. Sepsis or bacteremia (100 [34.7%]) and recent use of cocaine or other illicit drugs (39 [13.5%]) were the most common causes of type 2 MIs. A higher proportion of patients with type 2 MIs were younger than 40 years (47 of 288 [16.3%] vs 32 of 362 [8.8%]) and had lower current CD4 cell counts (median, 230 vs 383 cells/µL), lipid levels (mean [SD] total cholesterol level, 167 [63] vs 190 [54] mg/dL, and mean (SD) Framingham risk scores (8% [7%] vs 10% [8%]) than those with type 1 MIs or who underwent cardiac interventions. Conclusions and Relevance: Approximately half of all MIs among HIV-infected individuals were type 2 MIs caused by heterogeneous clinical conditions, including sepsis or bacteremia and recent use of cocaine or other illicit drugs. Demographic characteristics and cardiovascular risk factors among those with type 1 and type 2 MIs differed, suggesting the need to specifically consider type among HIV-infected individuals to further understand MI outcomes and to guide prevention and treatment.

Entities:  

Mesh:

Year:  2017        PMID: 28052152      PMCID: PMC5538773          DOI: 10.1001/jamacardio.2016.5139

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


  44 in total

Review 1.  Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review.

Authors:  David C Rhew; Myriam Bernal; Daniel Aguilar; Uchenna Iloeje; Matthew Bidwell Goetz
Journal:  Clin Infect Dis       Date:  2003-09-12       Impact factor: 9.079

2.  Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.

Authors:  E L Murphy; A C Collier; L A Kalish; S F Assmann; M F Para; T P Flanigan; P N Kumar; L Mintz; F R Wallach; G J Nemo
Journal:  Ann Intern Med       Date:  2001-07-03       Impact factor: 25.391

Review 3.  Cardiovascular risks of antiretroviral therapies.

Authors:  Kristin Mondy; Pablo Tebas
Journal:  Annu Rev Med       Date:  2007       Impact factor: 13.739

4.  Type 2 myocardial infarction in clinical practice.

Authors:  Tomasz Baron; Kristina Hambraeus; Johan Sundström; David Erlinge; Tomas Jernberg; Bertil Lindahl
Journal:  Heart       Date:  2014-10-20       Impact factor: 5.994

5.  Provoking conditions, management and outcomes of type 2 myocardial infarction and myocardial necrosis.

Authors:  Nathaniel R Smilowitz; Matthew C Weiss; Rina Mauricio; Asha M Mahajan; Kaitlyn E Dugan; Arvind Devanabanda; Claudia Pulgarin; Eugenia Gianos; Binita Shah; Steven P Sedlis; Martha Radford; Harmony R Reynolds
Journal:  Int J Cardiol       Date:  2016-05-13       Impact factor: 4.164

6.  Diabetes case identification methods applied to electronic medical record systems: their use in HIV-infected patients.

Authors:  Heidi M Crane; Joseph B Kadane; Paul K Crane; Mari M Kitahata
Journal:  Curr HIV Res       Date:  2006-01       Impact factor: 1.581

7.  Diagnosis of type 1 and type 2 myocardial infarction using a high-sensitivity cardiac troponin I assay with sex-specific 99th percentiles based on the third universal definition of myocardial infarction classification system.

Authors:  Yader Sandoval; Stephen W Smith; Karen M Schulz; MaryAnn M Murakami; Sara A Love; Jennifer Nicholson; Fred S Apple
Journal:  Clin Chem       Date:  2015-02-11       Impact factor: 8.327

8.  HIV infection and the risk of acute myocardial infarction.

Authors:  Matthew S Freiberg; Chung-Chou H Chang; Lewis H Kuller; Melissa Skanderson; Elliott Lowy; Kevin L Kraemer; Adeel A Butt; Matthew Bidwell Goetz; David Leaf; Kris Ann Oursler; David Rimland; Maria Rodriguez Barradas; Sheldon Brown; Cynthia Gibert; Kathy McGinnis; Kristina Crothers; Jason Sico; Heidi Crane; Alberta Warner; Stephen Gottlieb; John Gottdiener; Russell P Tracy; Matthew Budoff; Courtney Watson; Kaku A Armah; Donna Doebler; Kendall Bryant; Amy C Justice
Journal:  JAMA Intern Med       Date:  2013-04-22       Impact factor: 21.873

9.  Coronary heart disease in HIV-infected individuals.

Authors:  Judith S Currier; Anne Taylor; Felicity Boyd; Christopher M Dezii; Hugh Kawabata; Beth Burtcel; Jen-Fue Maa; Sally Hodder
Journal:  J Acquir Immune Defic Syndr       Date:  2003-08-01       Impact factor: 3.731

10.  Class of antiretroviral drugs and the risk of myocardial infarction.

Authors:  Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren
Journal:  N Engl J Med       Date:  2007-04-26       Impact factor: 91.245

View more
  32 in total

1.  Editorial Commentary: Clinical management of cardiovascular disease in HIV-infected patients.

Authors:  Alison Kearns; Tricia H Burdo; Xuebin Qin
Journal:  Trends Cardiovasc Med       Date:  2017-07-22       Impact factor: 6.677

2.  MicroRNA biomarkers associated with type 1 myocardial infarction in HIV-positive individuals.

Authors:  Neal Yuan; Rebecca Scherzer; Kahraman Tanriverdi; Jeffrey Martin; Smruti Rahalkar; Priscilla Hsue
Journal:  AIDS       Date:  2019-12-01       Impact factor: 4.177

3.  Association Between Bilirubin, Atazanavir, and Cardiovascular Disease Events Among People Living With HIV Across the United States.

Authors:  Heidi M Crane; Robin M Nance; Susan R Heckbert; Corey Ritchings; Lisa Rosenblatt; Matthew Budoff; Brian R Wood; David L Tirschwell; H Nina Kim; William C Mathews; Elvin Geng; Richard D Moore; Peter W Hunt; Joseph J Eron; Greer A Burkholder; Daniel R Drozd; Felicia C Chow; Kyra J Becker; Joseph R Zunt; Emily L Ho; Rizwan Kalani; Andrew Huffer; Bridget M Whitney; Michael S Saag; Mari M Kitahata; Joseph A C Delaney
Journal:  J Acquir Immune Defic Syndr       Date:  2019-08-15       Impact factor: 3.731

Review 4.  Epidemiology, pathophysiology, and prevention of heart failure in people with HIV.

Authors:  Arjun Sinha; Matthew Feinstein
Journal:  Prog Cardiovasc Dis       Date:  2020-01-24       Impact factor: 8.194

5.  Geriatric-HIV medicine: A science in its infancy.

Authors:  Giovanni Guaraldi; Andrea Cossarizza
Journal:  Virulence       Date:  2017-03-28       Impact factor: 5.882

Review 6.  HIV infection and coronary heart disease: mechanisms and management.

Authors:  Priscilla Y Hsue; David D Waters
Journal:  Nat Rev Cardiol       Date:  2019-06-10       Impact factor: 32.419

7.  Differentiation of Type 1 and Type 2 Myocardial Infarctions Among HIV-Infected Patients Requires Adjudication Due to Overlap in Risk Factors.

Authors:  Robin M Nance; Heidi M Crane; Corey Ritchings; Lisa Rosenblatt; Matthew Budoff; Susan R Heckbert; Daniel R Drozd; William C Mathews; Elvin Geng; Peter W Hunt; Matthew J Feinstein; Richard D Moore; Priscilla Hsue; Joseph J Eron; Greer A Burkholder; Benigno Rodriguez; Michael J Mugavero; Michael S Saag; Mari M Kitahata; Joseph A C Delaney
Journal:  AIDS Res Hum Retroviruses       Date:  2018-08-21       Impact factor: 2.205

Review 8.  HIV and Cardiovascular Disease: Update on Clinical Events, Special Populations, and Novel Biomarkers.

Authors:  Kaku So-Armah; Matthew S Freiberg
Journal:  Curr HIV/AIDS Rep       Date:  2018-06       Impact factor: 5.071

9.  Cumulative Human Immunodeficiency Viremia, Antiretroviral Therapy, and Incident Myocardial Infarction.

Authors:  Joseph A Delaney; Robin M Nance; Bridget M Whitney; Heidi M Crane; Jessica Williams-Nguyen; Mathew J Feinstein; Robert C Kaplan; David B Hanna; Matthew J Budoff; Daniel R Drozd; Greer Burkholder; Michael J Mugavero; William C Mathews; Richard D Moore; Joseph J Eron; Peter W Hunt; Elvin Geng; Michael S Saag; Mari M Kitahata; Susan R Heckbert
Journal:  Epidemiology       Date:  2019-01       Impact factor: 4.822

10.  Time to Recognize HIV Infection as a Major Cardiovascular Risk Factor.

Authors:  Priscilla Y Hsue; David D Waters
Journal:  Circulation       Date:  2018-09-11       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.